Evidence map›Paper›PMID 36976494›Full record

ArticleNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2023

Glioma Cells Expressing High Levels of ALDH5A1 Exhibit Enhanced Migration Transcriptional Signature in Patient Tumors.

Christina Piperi, Mirca S Saurty-Seerunghen, Georgia Levidou, Athanasia Sepsa, Eleni-Andriana Trigka, Alexia Klonou, Mariam Markouli, Dimitrios Strepkos, Anastasia Spyropoulou, Dimitrios S Kanakoglou and 5 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
11.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 40 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 3 countries.

Christina Piperi *Department of Biological Chemistry, National and Kapodistrian University of Athens, Athens, Greece.
Mirca S Saurty-Seerunghen *CNRS UMR8246, Inserm U1130, Sorbonne Université, Neuroscience Paris Seine-IBPS Laboratory, Paris, France.
Georgia LevidouDepartment of Pathology, Medical School, Klinikum Nuremberg, Paracelsus University, Nuremberg, Germany.
Athanasia SepsaDepartment of Pathology, Medical School, National and Kapodistrian University of Athens, 75 M. Asias Street, Athens, Greece.
Eleni-Andriana TrigkaDepartment of Pathology, Medical School, National and Kapodistrian University of Athens, 75 M. Asias Street, Athens, Greece.
Alexia KlonouDepartment of Biological Chemistry, National and Kapodistrian University of Athens, Athens, Greece.
Mariam MarkouliDepartment of Biological Chemistry, National and Kapodistrian University of Athens, Athens, Greece.
Dimitrios StrepkosDepartment of Biological Chemistry, National and Kapodistrian University of Athens, Athens, Greece.
Anastasia SpyropoulouDepartment of Biological Chemistry, National and Kapodistrian University of Athens, Athens, Greece.
Dimitrios S KanakoglouDepartment of Pathology, Medical School, National and Kapodistrian University of Athens, 75 M. Asias Street, Athens, Greece. kanakogloud@biol.uoa.gr.
Eleftheria LakiotakiDepartment of Pathology, Medical School, National and Kapodistrian University of Athens, 75 M. Asias Street, Athens, Greece.
Eleni A KaratrasoglouDepartment of Pathology, Medical School, National and Kapodistrian University of Athens, 75 M. Asias Street, Athens, Greece.
Efstathios BoviatsisDepartment of Neurosurgery, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Elias A El-Habr *CNRS UMR8246, Inserm U1130, Sorbonne Université, Neuroscience Paris Seine-IBPS Laboratory, Paris, France.
Penelope Korkolopoulou *Department of Pathology, Medical School, National and Kapodistrian University of Athens, 75 M. Asias Street, Athens, Greece. pkorkol@med.uoa.gr.ORCID 0000-0003-1883-3898
National and Kapodistrian University of Athens · GRCentre National de la Recherche Scientifique · FRNuremberg Hospital · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Accumulating data shows that altered metabolic activity contributes to glioma development. Recently, modulation of SSADH (succinic semialdehyde dehydrogenase) expression, implicated in the catabolism of GABA neurotransmitter, was shown to impact glioma cell properties, such as proliferation, self-renewal and tumorigenicity. The purpose of this study was to investigate the clinical significance of SSADH expression in human gliomas. Using public single-cell RNA-sequencing data from glioma surgical resections, we initially grouped cancer cells according to ALDH5A1 (Aldehyde dehydrogenase 5 family member A1) expression, which encodes SSADH. Gene ontology enrichment analysis of genes differentially expressed between cancer cells expressing high or low levels of ALDH5A1, highlighted enrichment in genes implicated in cell morphogenesis and motility. In glioblastoma cell lines, ALDH5A1 knockdown inhibited cell proliferation, induced apoptosis and reduced their migratory potential. This was accompanied by a reduction in the mRNA levels of the adherens junction molecule ADAM-15 and deregulation in the expression of EMT biomarkers, with increased CDH1 and decreased vimentin mRNA levels. Evaluation of SSADH expression in a cohort of 95 gliomas using immunohistochemistry showed that SSADH expression was significantly elevated in cancer tissues compared to normal brain tissues, without any significant correlation with clinicopathological characteristics. In summary, our data show that SSADH is upregulated in glioma tissues irrespective of the histological grade and its expression sustains glioma cell motility.

Indexed as

GlioblastomaGliomaSuccinate-Semialdehyde DehydrogenaseBiomarkersHumansALDH5A1 protein, humanBiomarkersSuccinate-Semialdehyde DehydrogenaseADAM-15ALDH5A1CDH1Cell motilityGene silencingGliomasPerinecrotic areasVimentin

Identifiers

PMID36976494
PMCPMC10275844
OpenAlexW4361190207

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.